scrollen

Betreff:

Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV

Schlagworte:

legal matter /​ amendment of forecast /​ budget figures /​ forecast

Eintritt der Insiderinformationen:

21.07.2024

Ergänzende Angaben:

Biofrontera AG: Legal dispute on import in the USA and resulting revised outlook


Angaben zum Inhalt:

scrollen

Inhalt der Ad-Hoc-Mitteilung:

Biofrontera AG: Legal dispute on import in the USA and resulting revised outlook

Leverkusen, Germany (pta008/​21.07.2024/​14:45 UTC+2) - Biofrontera AG has been sued by a USA competitor with the argument that Biofrontera infringes some competitors' lamps patents.

The competitor has filed two different processes, one for two patent infringements in front of the district court, and a second one before the ITC (International Trade Commission), aiming to prohibit the import in the USA of Biofrontera XL Lamp.

Biofrontera has requested initial legal advice and is currently in the process of evaluating its legal position. Biofrontera AG and its subsidiaries have signed a jointly defense agreement with Biofrontera Inc, to share legal expenses.

Costs for the ITC legal proceedings are expected to amount to US$5 million, to be shared between to two companies. The outlook for the business year 2024 needs to be revised as a result. ​Currently the company is about to establish the effects and will inform about a new outlook once there is more clarity about the situation.

Emitter: Biofrontera AG
Adresse: Hemmelrather Weg 201, 51377 Leverkusen
Country: Germany
Contact person: Investor Relations
Tel.: +49 (0) 214 87 63 20
Email: ir@biofrontera.com
Website: www.biofrontera.com
ISIN(s): DE000A4BGGM7 (Aktie)
Exchanges: Regulated Market in Dusseldorf, Regulated Market in Frankfurt, Free Market in Berlin, Free Market in Munich, Free Market in Stuttgart, Open Market in Tradegate
Quelle: https:/​/​www.pressetext.com/​news/​20240721008


Angaben zum Emittenten:

scrollen

Name:

Biofrontera AG

Adresse:

Hemmelrather Weg 201, 51377 Leverkusen

E-Mail-Adresse:

ir@biofrontera.com

Internet-Adresse::

http:/​/​www.biofrontera.com

ISIN:

DE000A4BGGM7 (Aktie)

Handelsplätze:

Regulated Market in Dusseldorf, Regulated Market in Frankfurt, Free Market in Berlin, Free Market in Munich, Free Market in Stuttgart, Open Market in Tradegate


Angaben zur Pflichtmitteilung:

scrollen

Veröffentlichung in elektronisch betriebenen Informationsverbreitungssystem:

pressetext, published over Bloomberg, Dow Jones Newswires and Thomson Reuters

Pflichtveröffentlichung am:

21.07.2024

Uhrzeit der Veröffentlichung:

14:45:00

Pflichtveröffentlichung in/​über:

pressetext, published over Bloomberg, Dow Jones Newswires and Thomson Reuters

Pflichtveröffentlichung am:

2024-07-21

Sprachen der Veröffentlichung:

Englisch